Prihlásiť sa Zaregistrujte sa zadarmo

Návratnosť aktív spoločnosti Adaptimmune Therapeutics Plc

Aká je hodnota metriky Návratnosť aktív spoločnosti Adaptimmune Therapeutics Plc?

Hodnota metriky Návratnosť aktív spoločnosti Adaptimmune Therapeutics Plc je -25.02%

Aká je definícia metriky Návratnosť aktív?



Návratnosť aktív (Return on assets - ROA) je rentabilita aktív. Vypočíta sa vydelením celkového príjmu priemerom celkových aktív.

The return on assets (ROA) tells you what the company can do with what it has, i.e. how many dollars of earnings they derive from each dollar of assets they control. It's a useful number for comparing competing companies in the same industry. The number will vary widely across different industries. Return on assets gives an indication of the capital intensity of the company, which will depend on the industry; companies that require large initial investments will generally have lower return on assets. ROAs over 5% are generally considered good.

Návratnosť aktív spoločností v sektore Health Care sektor na NASDAQ v porovnaní so spoločnosťou Adaptimmune Therapeutics Plc

Čomu sa venuje spoločnosť Adaptimmune Therapeutics Plc?

adaptimmune llc is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary t-cell receptor platform that has the potential to transform the treatment of cancer. established in 2008, the company has grown from being privately held to one of the most successful biopharmaceutical initial public offerings (ipo) in 2015. with u.s. operations based in philadelphia, pa, adaptimmune is a company founded on strong science that has led to a robust pipeline of immuno-oncology product candidates, a growing research & development platform and ongoing plans for expansion. for more information about adaptimmune, please visit www.adaptimmune.com. if interested in joining our fast growing team, click on the careers tab of this page.

Firmy s metrikou návratnosť aktív podobnou spoločnosti Adaptimmune Therapeutics Plc